Emerging Opportunities in In Situ Hybridization
This article was originally published in Start Up
Executive Summary
In-situ hybridization (ISH) is a powerful method of genetic testing. But it has not yet found a place in the clinical laboratory. In addition to technical, patent and regulatory obstacles, participants will confront a fragmented market composed currently of high-priced, low-volume tests. Many scientists believe ISH will have an important role in the clinical laboratory, while others see it mostly as an interim technology likely to be superseded by easier-to-use DNA chips.
You may also be interested in...
Vysis Preps For Prime Time
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.